RhumbLine Advisers
GYRE icon

RhumbLine Advisers’s Gyre Therapeutics GYRE Stock Holding History

RhumbLine Advisers’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Buy
16,865
+3,749
+29% +$25.5K ﹤0.01% 3495
2026
Q1 		$91.4K Sell
13,116
-916
-7% -$7.11K ﹤0.01% 3447
2025
Q4 		$99.1K Buy
14,032
+600
+4% +$4.63K ﹤0.01% 3479
2025
Q3 		$100K Sell
13,432
-2,754
-17% -$20.9K ﹤0.01% 3519
2025
Q2 		$119K Buy
16,186
+5,045
+45% +$44K ﹤0.01% 3472
2025
Q1 		$86K Buy
11,141
+709
+7% +$7.78K ﹤0.01% 3443
2024
Q4 		$126K Buy
10,432
+8
+0.1% +$102 ﹤0.01% 3404
2024
Q3 		$131K Buy
10,424
+133
+1% +$1.72K ﹤0.01% 3425
2024
Q2 		$123K Buy
+10,291
New +$141K ﹤0.01% 3453
2021
Q2 		– Sell
-4,398
Closed -$166K – 3045
2021
Q1 		$166K Buy
4,398
+440
+11% +$20.1K ﹤0.01% 2869
2020
Q4 		$187K Buy
3,958
+692
+21% +$30K ﹤0.01% 2859
2020
Q3 		$105K Buy
3,266
+371
+13% +$14.5K ﹤0.01% 2856
2020
Q2 		$127K Buy
+2,895
New +$136K ﹤0.01% 2915
2019
Q2 		– Sell
-2,243
Closed -$136K – 2983
2019
Q1 		$136K Sell
2,243
-24
-1% -$1.54K ﹤0.01% 2822
2018
Q4 		$134K Buy
2,267
+683
+43% +$50.4K ﹤0.01% 2836
2018
Q3 		$128K Buy
1,584
+35
+2% +$2.77K ﹤0.01% 2832
2018
Q2 		$136K Buy
+1,549
New +$272K ﹤0.01% 2834
2014
Q2 		– Sell
-48
Closed -$178K – 3032
2014
Q1 		$178K Sell
48
-1
-2% -$3.7K ﹤0.01% 2812
2013
Q4 		$161K Sell
49
-3
-6% -$11.8K ﹤0.01% 2885
2013
Q3 		$220K Sell
52
-1
-2% -$4.02K ﹤0.01% 2730
2013
Q2 		$178K Buy
+53
New +$202K ﹤0.01% 3039

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

RhumbLine Advisers's GYRE Position: Q2 2026 in Review

RhumbLine Advisers increased its Gyre Therapeutics (GYRE) stake by 29% in Q2 2026, buying an estimated $25.5K and bringing the position to 16,865 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #3495.

RhumbLine Advisers first reported a position in GYRE in Q2 2013 and has held it in 21 quarters since. The position peaked at $220K in Q3 2013. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • RhumbLine Advisers held 16,865 shares of Gyre Therapeutics worth $111K as of Q2 2026.
  • RhumbLine Advisers bought 3,749 Gyre Therapeutics shares in Q2 2026, an estimated $25.5K.
  • Gyre Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3495 holding.
  • RhumbLine Advisers first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 21 quarters since.
  • RhumbLine Advisers's Gyre Therapeutics position peaked at $220K in Q3 2013.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.